Maze Therapeutics (MAZE) Total Liabilities (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Total Liabilities data on file, last reported at $78.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 91.33% year-over-year to $78.0 million; the trailing twelve-month figure through Mar 2026 stood at $78.0 million (up 91.33% YoY), and the FY2025 full-year result was $42.2 million, down 3.38% from the prior year.
• Total Liabilities climbed to $78.0 million in Q1 2026, from $42.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $78.0 million in Q1 2026 to a low of $40.8 million in Q1 2025.
• A 3-year average of $48.1 million and a median of $42.4 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities dropped 3.38% in 2025 and surged 91.33% in 2026, its largest moves.
• Tracing MAZE's Total Liabilities over 3 years: stood at $43.6 million in 2024, then fell by 3.38% to $42.2 million in 2025, then surged by 85.03% to $78.0 million in 2026.
• Business Quant data shows MAZE's Total Liabilities at $78.0 million in Q1 2026, $42.2 million in Q4 2025, and $42.6 million in Q3 2025.